Laborie Bolsters Obstetrics Portfolio With Clinical Innovations Buy
Executive Summary
Laborie Medical Technologies has inked a $525m deal to buy obstetrics device maker Clinical Innovations. The acquisition adds a suite of neonatal and fetal care devices to Laborie’s existing obstetrics portfolio.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2019
Device financing during 2019’s final quarter totaled $1.6bn, a substantial decrease from Q3’s $4.05bn. Merger and acquisition activity, almost doubled from the previous quarter reaching $6.1bn; Stryker’s 4.7bn takeover of Wright Medical was the only billion-dollar transaction. Financings by diagnostics/research players totaled $1.3bn (the lowest quarter of the year) and eight companies were acquired, five of which together were valued at $981m.
Laborie To Buy Cogentix For $239m
The deal adds Cogentix' Urgent PC neuromodulation system for urinary incontinence, PrimeSight cystoscopy system, and Macroplastique soft-tissue bulking agent to treat female stress urinary incontinence to Laborie's range of urology and gynecology products.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.